Coronavirus Vaccine Trial India Emergency Approval; AIIMS Director Randeep Guleria Latest News Update | AIIMS director said - Vaccine can get emergency approval in India by January » India News
Connect with us

India News

Coronavirus Vaccine Trial India Emergency Approval; AIIMS Director Randeep Guleria Latest News Update | AIIMS director said – Vaccine can get emergency approval in India by January

Published

on

  • Hindi news
  • Coronavirus
  • Coronavirus Vaccine Trial India Emergency Approval; AIIMS Director Randeep Guleria Latest News Update

Fed up with Ads? Install Dainik Bhaskar app for news without ads

17 minutes ago

AIIMS director Dr. Randeep Guleria claims that the corona vaccine will be approved in the country in late December or early January. (File photo)

The best news has come for the country. The corona vaccine may receive emergency approval in late December or early January. Dr. Randeep Guleria, director of Delhi-AIIMS, informed about this on Thursday.

Dr. Guleria has said that some vaccines in India are now in the final stage trials. We hope that by the end of December or early January, any of them will get emergency approval from the drug regulator. After that the vaccination will start. Actually, six vaccines are currently in operation in India. This includes the Oxford-AstraZeneca and Bharat Biotech vaccine phase-3 trials.

The clinical trials of Phase-3 clinical trials of Oxford-AstraZeneca’s vaccine-Kovyshield have come internationally. Adar Poonawala, the CEO of Serum Institute of India (SII), which is making it in India, said last week that they are preparing to apply for emergency approval soon.

Dr. Guleria said on Thursday that based on the data so far, it can be said that the vaccine is safe and effective. There will be no compromise with the safety and affixes of the vaccine. 70 to 80 thousand volunteers have been vaccinated. No serious side effects have been reported so far. The data suggests that the short-term vaccine is safe.

Dose of coviShield vaccine is ready for supply in Serum Institute of India's cold storage.  Their supply will start as soon as emergency approval is received.  The company is going to supply 100 million doses in India.

Dose of coviShield vaccine is ready for supply in Serum Institute of India’s cold storage. Their supply will start as soon as emergency approval is received. The company is going to supply 100 million doses in India.

China had approved its 4 and Russia 2 vaccines before clinical trials were completed. The UK then gave emergency approval to the mRNA vaccine produced by US company Pfizer and its German partner Bioentech on 2 December.

Advertisement

bareilly